Your fact-checks will appear here
Preclinical studies demonstrating ivermectin's anticancer effects, including cytotoxicity, anti-proliferative, and anti-angiogenic effects in various cancer models.
Preclinical work identifies strongest anticancer signals for ivermectin in breast cancer, hematologic malignancies (notably leukemia), hepatocellular carcinoma, and several drug-resistant solid tumor ...
Standard single-dose antiparasitic regimens of oral ivermectin produce plasma levels in the low nanomolar range, whereas multi‑day oncology schedules being tested raise both total exposure and peak le...
Preclinical literature shows repeated, drug‑level interactions between ivermectin and multiple chemotherapy or targeted agents—mostly beneficial pharmacodynamic synergies (enhanced tumor cell kill, re...
both reduce PAK1-driven signaling in preclinical cancer models, but they do so by different molecular routes and with different translational implications: ivermectin promotes proteasome-mediated degr...
No explicit pharmacovigilance case reports documenting confirmed drug–drug interactions between (antiemetics, growth factors, or antibiotics) are identified in the provided reporting; instead, the lit...
Preclinical research ties ’s anticancer activity to at least three interlocking mechanisms: suppression of Wnt/β‑catenin signaling, inhibition of the PAK1/Akt/mTOR axis with induction of autophagy/apo...